natgillin/translations-raw huggingface dataset:
The effect of ofatumumab on patients with prolonged QT intervals (e.g. acquired or congenital) is unknown.
Učinak ofatumumaba na bolesnike s produljenim QT-intervalom (npr. stečenim ili prirođenim) nije poznat.
The effect of OPTISON on pulmonary haemodynamics was studied in a prospective, open-label study of 30 patients scheduled for pulmonary artery catheterisation, including 19 with an elevated baseline pulmonary arterial systolic pressure (PASP) (>35 mmHg; mean 70.1±33.0 mmHg; range 36.0-176.0 mmHg) and 11 with a normal PASP (≤35 mmHg; mean 29.3±4.6 mmHg; range 22.0-35.0 mmHg).
Učinak OPTISONA na plućnu hemodinamiku proučavan je u prospektivnom otvorenom kliničkom ispitivanju u kojem je sudjelovalo 30 bolesnika naručenih za kateterizaciju plućne arterije, uključujući njih 19 s povišenim plućnim arterijskim sistoličkim tlakom (PAST) (>35 mmHg; srednja vrijednost 70,1±33,0 mmHg; raspon 36,0-176,0 mmHg) i 11 s normalnim PAST-om (≤35 mmHg; srednja vrijednost 29,3±4,6 mmHg; raspon 22,0-35,0 mmHg).
The effect of orlistat in individuals with hepatic and/or renal impairment has not been studied (see section 4.4).
Učinci orlistata u osoba s jetrenim i/ili bubrežnim oštećenjima nisu istraženi (vidjeti odjeljak 4.4).
The effect of palonosetron on QTc interval was evaluated in a double blind, randomised, parallel, placebo and positive (moxifloxacin) controlled trial in adult men and women.
Učinak palonosetrona na QTc interval procijenjen je u dvostruko slijepom, randomiziranom, usporednom placebom i pozitivno (moksifloksacin) kontroliranom ispitivanju u odraslih muškaraca i žena.
The effect of pioglitazone (45 mg monotherapy vs. placebo) was studied in a small 18-week trial in type 2 diabetics.
Učinak pioglitazona (45 mg monoterapija naspram placeba) ispitivao se u malom ispitivanju u trajanju od 18 tjedana u bolesnika sa šećernom bolešću tipa 2.
The effect of pioglitazone (45 mg monotherapy vs. placebo) was studied in a small 18-week trial in type 2 diabetics.
Učinak pioglitazona (monoterapija dozom od 45 mg naspram placeba) ispitivao se u malom ispitivanju u trajanju od 18 tjedana u bolesnika sa šećernom bolešću tipa 2.
The effect of pioglitazone (45 mg monotherapy vs. placebo) was studied in a small 18-week trial in type 2 diabetics.
Učinak pioglitazona (monoterapija dozom od 45 mg naspram placeba) proučen je u malom ispitivanju u trajanju od 18 tjedana u osoba sa šećernom bolešću tipa 2.
The effect of pioglitazone (45 mg monotherapy vs. placebo) was studied in a small 18-week trial in type 2 diabetics.
Učinak pioglitazona (monoterapija dozom od 45 mg naspram placebo) ispitivao se u malom ispitivanju u trajanju od 18 tjedana u bolesnika sa šećernom bolešću tipa 2.
The effect of pioglitazone (45 mg monotherapy vs. placebo) was studied in a small 18-week trial in type 2 diabetics.
Učinak pioglitazona (monoterapija dozom od 45 mg naspram placebo) proučen je u malom ispitivanju u trajanju od 18 tjedana u osoba sa šećernom bolešću tipa 2.
The effect of pioglitazone (45 mg monotherapy vs. placebo) was studied in a small 18-week trial in type 2 diabetics.
Učinak pioglitazona (monoterapija dozom od 45 mg u odnosu na placebo) ispitivao se u malom ispitivanju u trajanju od 18 tjedana u bolesnika sa šećernom bolešću tipa 2.
The effect of Praluent on cardiovascular morbidity and mortality has not yet been determined.
Učinak lijeka Praluent na kardiovaskularni pobol i smrtnost još nije utvrđen.
The effect of Pramipexole Teva on the unborn child is not known.
Učinci Pramipeksol Teva na nerođenu djecu su nepoznati.
The effect of pressor amines may be decreased, but not sufficiently to preclude their use;
Učinak presornih amina može biti smanjen, ali ne dovoljno da se isključi njihova primjena;
The effect of PritorPlus may be reduced when you take NSAIDs (non steroidal anti-inflammatory medicines, e.g. aspirin or ibuprofen).
Učinak PritorPlusa se može smanjiti dok uzimate NSAIL-ove (nesteroidni protuupalni lijekovi, npr. acetilsalicilna kiselina ili ibuprofen).
The effect of PritorPlus may be reduced when you take NSAIDs (non steroidal anti-inflammatory medicines, e.g. aspirin or ibuprofen).
Učinak PritorPlusa se može smanjiti dok uzimate NSAIL-ove (nesteroidni protuupalni lijekovi, npr. acetilsalicilnu kiselinu ili ibuprofen).
The effect of race on metabolism of pitolisant has not been evaluated.
Nije istraživan utjecaj rase na metabolizam pitolizanta.
The effect of race on metabolism of sodium oxybate has not been evaluated.
Nije istraživan utjecaj rase na farmakokinetiku natrijeva oksibata.
The effect of renal impairment on the CL of nivolumab was evaluated in patients with mild (GFR < 90 and ≥ 60 mL/min/1.73 m2; n = 379), moderate (GFR < 60 and ≥ 30 mL/min/1.73 m2; n = 179), or severe (GFR < 30 and ≥ 15 mL/min/1.73 m2; n = 2) renal impairment compared to patients with normal renal function (GFR ≥ 90 mL/min/1.73 m2; n = 342) in population PK analyses.
(GFR < 90 i ≥ 60 ml/min/1,73 m2; n = 379), umjerenim (GFR < 60 i ≥ 30 ml/min/1,73 m2; n = 179) ili teškim (GFR < 30 i ≥ 15 ml/min/1,73 m2; n = 2) oštećenjem bubrežne funkcije u usporedbi s bolesnicima s normalnom bubrežnom funkcijom (GFR ≥ 90 ml/min/1,73 m2; n = 342) u populacijskim PK analizama.
The effect of Repatha on cardiovascular morbidity and mortality has not yet been demonstrated.
Učinak lijeka Repatha na kardiovaskularni pobol i smrtnost još nije dokazan.
The effect of Repatha on cardiovascular morbidity and mortality has not yet been determined.
Učinak lijeka Repatha na kardiovaskularni pobol i smrtnost još nije utvrđen.
The effect of reslizumab in patients with asthma and elevated sputum eosinophil counts (at least 3%) was evaluated in a 15-week, phase 2, randomised, double-blind, placebo-controlled clinical study with reslizumab 3 mg/kg.
Učinak reslizumaba u bolesnika s astmom i povećanim brojem eozinofila u sputumu (najmanje 3 %) bio je procijenjen u 15-tjednom, randomiziranom, dvostruko slijepom, placebom kontroliranom kliničkom ispitivanju faze 2 u kojem se davao u dozi od 3 mg/kg.
The effect of Resolor on spontaneous bowel movements (SBM) also proved to be statistically superior to placebo for the portion of patients that had an increase of ≥1 SBM/week over the 12-week treatment period.
Učinak lijeka Resolor na spontano pražnjenje crijeva također se pokazao statistički superiornim placebu u dijelu bolesnika koji su imali povećanje od ≥1 spontanog pražnjenja crijeva na tjedan u 12- tjednom razdoblju liječenja.
The effect of selexipag on progression of PAH was demonstrated in a multi-centre, long-term (maximum duration of exposure approximately 4.2 years), double-blind, placebo-controlled, parallel-group, event-driven Phase 3 study in 1,156 patients with symptomatic (WHO FC I–IV) PAH.
Utjecaj seleksipaga na progresiju PAH-a pokazan je u multicentričnom, dugoročnom (najdulje trajanje izloženosti približno 4,2 godine), dvostruko slijepom, placebom kontroliranom, događajima oblikovanom, ispitivanju paralelnih skupina faze 3 u 1156 bolesnika sa simptomatskim (WHO FC I
The effect of severe hepatic impairment (Child-Pugh Class C) on the pharmacokinetics of elvitegravir, cobicistat, or tenofovir alafenamide has not been studied.
Utjecaj teškog oštećenja funkcije jetre (Child-Pugh, stadij C) na farmakokinetiku elvitegravira, kobicistata ili tenofoviralafenamida nije ispitan.
The effect of severe hepatic impairment (Child-Pugh Class C) on the pharmacokinetics of tenofovir alafenamide has not been studied.
Utjecaj teškog oštećenja funkcije jetre (Child-Pugh, stadij C) na farmakokinetiku tenofoviralafenamida nije ispitan.
The effect of shampooing or immersion in water of the animal has not been tested and should be avoided.
Iako utjecaj čestog šamponiranja ili uranjanja u vodu nije ispitan, isto bi trebalo izbjegavati.
The effect of stopping treatment on long-term disease outcome after the achievement of a cytogenetic or molecular response [including complete cytogenetic response (CCyR), major molecular response (MMR) and MR4.5] has not been investigated.
Učinak prekida liječenja na dugoročan ishod bolesti nakon dosegnuća citogenetskog ili molekularnog odgovora [uključujući potpun citogenetski odgovor (engl. complete cytogenetic response; CCyR), značajan molekularni odgovor (engl. major molecular response, MMR) i MR4,5] nije ispitivan.
The effect of sunscreen on the absorption of oxybutynin when applied 30 minutes before or 30 minutes after Kentera application was evaluated in a single-dose randomised crossover study (N=16).
Učinak sunčane zaštite na apsorpciju oksibutinina kada se primjenjuje 30 minuta prije ili 30 minuta nakon primjene Kentere procijenjen je u randomiziranom ispitivanju s jednokratnom dozom i s križnom zamjenom skupina (N=16).
The effect of Synflorix on nasopharyngeal carriage was studied in 2 double-blind randomised studies using an inactive control: in the nested study of FinIP in Finland (5,023 subjects) and in COMPAS (1,700 subjects).
Učinak cjepiva Synflorix na nazofaringealno kliconoštvo ispitan je u dva dvostruko slijepa, randomizirana ispitivanja s neaktivnom kontrolom: u ugniježđenom ispitivanju u sklopu ispitivanja FinIP u Finskoj (5023 ispitanika) te u ispitivanju COMPAS (1700 ispitanika).
The effect of Telmisartan Teva Pharma may be reduced when you take NSAIDs (non steroidal anti- inflammatory medicines, e.g. aspirin or ibuprofen) or corticosteroids.
Učinak Telmisartana Teva Pharma se može smanjiti kada uzimate NSAIL (nesteroidne protupalne lijekove, npr. aspirin ili ibuprofen) ili kortikosteroide.
The effect of the combination on the patient’s QTc interval should be evaluated with pre- and post-dose ECGs.
Učinak kombinacije na QTc interval u bolesnika je potrebno procijeniti EKG-om prije i poslije primjene doze.
The effect of the lower dose of ADROVANCE (alendronate 70 mg/vitamin D3 2,800 IU) on vitamin D status was demonstrated in a 15-week, multinational study that enrolled 682 osteoporotic post- menopausal women (serum 25-hydroxyvitamin D at baseline: mean, 56 nmol/l [22.3 ng/ml]; range, 22.5-225 nmol/l [9-90 ng/ml]).
Učinak niže doze lijeka ADROVANCE (alendronat 70 mg/vitamin D3 2800 IU) na razine vitamina D dokazan je u multinacionalnom ispitivanju u trajanju od 15 tjedana koje je obuhvatilo 682 žene u postmenopauzi s osteoporozom (početne vrijednosti 25-hidroksivitamina D u serumu: srednja vrijednost 56 nmol/l [22,3 ng/ml]; raspon 22,5-225 nmol/l [9-90 ng/ml]).
The effect of the lower dose of ADROVANCE (alendronate 70 mg/vitamin D3 2,800 IU) plus an additional 2,800 IU Vitamin D3 for a total of 5,600 IU (the amount of vitamin D3 in the higher dose of ADROVANCE) once weekly was demonstrated in a 24-week, extension study that enrolled
U 24-tjednom nastavku ispitivanja koje je uključilo 619 žena u postmenopauzi s osteoporozom dokazan je učinak niže doze lijeka ADROVANCE (alendronat 70 mg/vitamin D3 2800 IU) uz dodatak 2800 IU vitamina D3, što čini ukupno 5600 IU (količina vitamina D3 u višoj dozi lijeka ADROVANCE) jedanput na tjedan.
The effect of the lower dose of FOSAVANCE (alendronate 70 mg/vitamin D3 2,800 IU) on vitamin D status was demonstrated in a 15-week, multinational study that enrolled 682 osteoporotic post-menopausal women (serum 25-hydroxyvitamin D at baseline: mean, 56 nmol/l [22.3 ng/ml]; range, 22.5-225 nmol/l [9-90 ng/ml]).
Učinak lijeka FOSAVANCE u nižoj dozi (alendronat 70 mg/vitamin D3 2800 IU) na razine vitamina D ustanovljen je u multinacionalnom ispitivanju u trajanju od 15 tjedana koje je obuhvatilo 682 žene u postmenopauzi s osteoporozom (početne vrijednosti 25-hidroksivitamina D u serumu: srednja vrijednost 56 nmol/l [22,3 ng/ml]; raspon 22,5-225 nmol/l [9-90 ng/ml]).
The effect of the lower dose of VANTAVO (alendronate 70 mg/vitamin D3 2800 IU) on vitamin D status was demonstrated in a 15-week, multinational study that enrolled 682 osteoporotic post-menopausal women (serum 25-hydroxyvitamin D at baseline: mean, 56 nmol/l [22.3 ng/ml]; range, 22.5-225 nmol/l [9-90 ng/ml]).
Učinak lijeka VANTAVO u nižoj dozi (alendronat 70 mg/vitamin D3 2800 IU) na razine vitamina D ustanovljen je u multinacionalnom ispitivanju u trajanju od 15 tjedana koje je obuhvatilo 682 žene u postmenopauzi s osteoporozom (početne vrijednosti 25-hidroksivitamina D u serumu: srednja vrijednost 56 nmol/l [22,3 ng/ml]; raspon 22,5-225 nmol/l [9-90 ng/ml]).
The effect of the medicine was compared with placebo (a dummy treatment) and the main measure of effectiveness was the proportion of patients who responded to treatment for at least 18 weeks, as shown by a 50% reduction (‘partial response’) or complete disappearance (‘complete response’) of tumours and symptoms of the disease.
Djelovanje lijeka uspoređeno je s placebom (lažnim liječenjem), a glavna mjera djelotvornosti bio je udio bolesnika koji su odgovorili na liječenje tijekom najmanje 18 tjedana, što je demonstrirano 50%-tnim smanjenjem („djelomičan odgovor”) ili potpunim nestankom („potpuni odgovor”) tumora i simptoma bolesti.
The effect of the vaccine in the per-protocol analysis was a 9 % reduction (95 % CI: 3, 15) in recurrent AOM (defined as 3 episodes in six months or 4 episodes in one year) or a 23 % (95 % CI: 7,36) reduction for recurrent AOM (5 episodes in six months or 6 episodes in one year).
Prema analizi populacije prema protokolu, cjepivo je smanjilo redicivirajuće akutne upale srednjeg uha (definirane kao 3 epizode u šest mjeseci ili 4 epizode u jednoj godini) za 9% (95 % CI: 3, 15) odnosno recidivirajuću akutnu upalu srednjeg uha (5 epizoda u šest mjeseci ili 6 epizoda u jednoj godini) za 23% (95% CI: 7, 36).
The effect of this medicine on human fertility has not been investigated.
Učinak ovog lijeka na ljudsku plodnost nije istražen.
The effect of tolcapone on the pharmacokinetics of other drugs metabolised by COMT such as -methyldopa, dobutamine, apomorphine, adrenaline and isoprenaline have not been evaluated.
Učinak tolkapona na farmakokinetiku drugih lijekova metaboliziranih COMT- om, kao što su -metildopa, dobutamin, apomorfin, adrenalin i izoprenalin još nije procijenjen.
The effect of Tolucombi may be reduced when you take NSAIDs (non steroidal anti-inflammatory medicines, e.g. aspirin or ibuprofen).
Učinak lijeka Tolucombi se može smanjiti dok uzimate NSAIL (nesteroidne protuupalne lijekove, npr. acetilsalicilnu kiselinu ili ibuprofen).
The effect of treatment initiation with a dosing regimen of Invirase/ritonavir 500 /100 mg twice daily in combination with 2 NRTIs for the first 7 days of treatment followed by Invirase/ritonavir 1000 / 100 mg twice daily in combination with 2 NRTIs in the subsequent 7 days on QTc interval, PK, and viral load was evaluated in an open-label 2-week observational study in 23 HIV-1 infected, treatment- naïve patients initiating Invirase/ritonavir therapy.
Učinak započinjanja liječenja lijekovima Invirase/ritonavir režimom doziranja od 500/100 mg dvaput na dan u kombinaciji s 2 NRTI-ja tijekom prvih 7 dana liječenja, nakon kojih slijedi 7 dana liječenja lijekovima Invirase/ritonavir u dozi od 1000/100 mg dvaput na dan u kombinaciji s 2 NRTI-ja, na QTc-interval, farmakokinetiku i virusno opterećenje ocijenjen je u 2-tjednom otvorenom opservacijskom ispitivanju u 23 prethodno neliječena bolesnika s HIV-1 infekcijom koji su započinjali liječenje lijekovima Invirase/ritonavir.
The effect of treatment with Protopic on the developing immune system in children, especially the young, has not been established.
Učinak liječenja Protopicom na razvoj imunološkog sustava u djece, osobito male, nije ustanovljen.
The effect of TRISENOX on your ability to drive is not known.
Učinak TRISENOXA na Vašu sposobnost vožnje nije poznata.
The effect of ustekinumab on human fertility has not been evaluated (see section 5.3).
Djelovanje ustekinumaba na plodnost u ljudi nije procijenjeno (vidjeti dio 5.3).
The effect of Volibris on human testicular function and male fertility is not known.
Utjecaj lijeka Volibris na funkciju testisa muškaraca i na plodnost muškaraca nije poznat.
The effect of voriconazole on
Nije poznat učinak vorikonazola ni
The effect of voriconazole on either erythromycin or azithromycin is unknown
Nije poznat učinak vorikonazola ni na eritromicin ni na azitromicin.
The effect of Xeristar 60 mg once a day in elderly depressed patients (65 years) was specifically examined in a study that showed a statistically significant difference in the reduction of the HAMD17 score for duloxetine-treated patients compared to placebo.
Učinak lijeka Xeristar u dozi od 60 mg jednom dnevno u starijih depresivnih bolesnika (≥ 65 godina) posebno je ispitivan u ispitivanju koje je pokazalo statistički značajnu razliku u smanjenju broja bodova na HAMD17 ljestvici u bolesnika liječenih duloksetinom u odnosu na one koji su uzimali placebo.
The effect on human fertility is unknown.
Utjecaj na plodnost u ljudi nije poznat.
The effect on intra-ocular pressure or the known effects of systemic beta-blockade may be potentiated when timolol is given to patients already receiving a systemic beta- blocking agent.
Postoji mogućnost pojačavanja djelovanja na intraokularni tlak ili pojačavanja poznatih učinaka sistemske beta-blokade kada se timolol primijeni kod bolesnika koji već uzimaju sistemski beta- blokator.
The effect on intra-ocular pressure or the known effects of systemic beta-blockade may be potentiated when timolol is given to the patients already receiving a systemic beta- blocking agent.
Postoji mogućnost pojačavanja djelovanja na intraokularni tlak ili pojačavanja poznatih učinaka sistemske beta-blokade kada se timolol primijeni kod bolesnika koji već uzimaju sistemski beta- blokator.
The effect on intra-ocular pressure or the known effects of systemic beta-blockade may be potentiated when timolol is given to the patients already receiving a systemic beta-blocking medicinal product.
Učinak na intraokularni tlak ili poznati učinci sistemske beta blokade mogu biti pojačani kada se timolol daje bolesnicima koji već primaju sistemski beta blokator.
The effect was progressively decreased with administration of an extended release formulation (increased of Cmax by about 90 % and AUC by about 70 %) or administration of multiple doses of verapamil (increased of Cmax by about 60 % and AUC by about 50 %).
Učinak se progresivno smanjio s primjenom formulacije s produljenim oslobađanjem (povećani Cmax za oko 90 % i AUC za oko 70 %) ili primjenom višestrukih doza verapamila (povećani Cmax za oko 60 % i AUC za oko 50 %).
The effective (peak to trough) half-life of lopinavir over a 12 hour dosing interval averaged 5 – 6 hours, and the apparent oral clearance (CL/F) of lopinavir is 6 to 7 l/h.
Efektivno poluvrijeme lopinavira (od najviše do najniže koncentracije), pri doziranju u razmacima po 12 sati, iznosilo je u prosjeku 5-6 sati, a prividni klirens lopinavira nakon peroralno uzete doze (CL/F) iznosio je 6 do 7 l/h.
The effective dose (E) resulting from administration of 185 MBq of DaTSCAN injection is 4.35 mSv (per 70 kg individual).
Efektivna doza (E) nakon primjene 185 MBq DaTSCAN-a je 4,35 mSv (po pojedincu tjelesne težine 70 kg).
The effective dose has been calculated by using the absorbed doses determined for each individual organ, taking into account the weighting factors (radiation and tissue) to use according to the recommendations of the ICRP (International Commission of Radiological Protection,
Učinkovita doza izračunata je pomoću utvrđenih apsorbiranih doza za svaki pojedinačni organ, uzimajući u obzir težinske čimbenike (radijacije i tkiva) prema preporukama ICRP-a (International Commission of Radiological Protection; Međunarodna komisija za radiološku zaštitu,
The effective dose range of ABILIFY solution for injection is 5.25- 15 mg as a single injection.
Raspon učinkovitih doza ABILIFY otopine za injekciju iznosi 5,25-15 mg u obliku jednokratne injekcije.
The effectiveness and safety of eltrombopag have not been established for use in other thrombocytopenic conditions including chemotherapy-induced thrombocytopenia or MDS.
Učinkovitost i sigurnost eltrombopaga nije utvrđena za liječenje drugih stanja s trombocitopenijom uključujući kemoterapijom izazvanu trombocitopeniju ili MDS.
The effectiveness of a two-dose primary series has not been established against pneumonia or acute otitis media.
Učinkovitost primarne serije s dvije doze protiv pneumonije i akutne upale srednjeg uha nije ustanovljena.
The effectiveness of Abilify in preventing symptoms from returning was assessed in three studies lasting up to a year, two of which used haloperidol (another antipsychotic medicine) as a comparator.
Djelotvornost lijeka Abilify u sprječavanju povratka simptoma procijenjena je u tri ispitivanja koja su trajala do godine dana od kojih su dva koristila haloperidol (drugi antipsihotik) kao usporedni lijek.
The effectiveness of ABILIFY in the treatment of schizophrenia and Bipolar I Disorder in patients aged 65 years and older has not been established.
Učinkovitost lijeka ABILIFY u liječenju shizofrenije i bipolarnog poremećaja tipa I u bolesnika u dobi od 65 godina i starijih nije ustanovljena.
The effectiveness of ABILIFY solution for injection in patients aged 65 years and older has not been established.
Učinkovitost ABILIFY otopine za injekciju u bolesnika u dobi od 65 godina i starijih nije ustanovljena.
The effectiveness of Aripiprazole Accord in the treatment of schizophrenia and Bipolar I Disorder in patients aged 65 years and older has not been established.
Učinkovitost lijeka Aripiprazol Accord u liječenju shizofrenije i bipolarnog poremećaja tipa I u bolesnika u dobi od 65 godina i starijih nije ustanovljena.
The effectiveness of aripiprazole in the treatment of schizophrenia and Bipolar I Disorder in patients aged 65 years and older has not been established.
Učinkovitost lijeka Aripiprazole Mylan Pharma u liječenju shizofrenije i bipolarnog poremećaja tipa I u bolesnika u dobi od 65 godina i starijih nije ustanovljena.
The effectiveness of Aripiprazole Sandoz in the treatment of schizophrenia and Bipolar I Disorder in patients aged 65 years and older has not been established.
Učinkovitost lijeka Aripiprazol Sandoz u liječenju shizofrenije i bipolarnog poremećaja tipa I u bolesnika u dobi od 65 godina i starijih nije ustanovljena.
The effectiveness of Bravecto against fleas and ticks was investigated in both laboratory and field studies.
Djelovanje VMP-a Bravecto protiv buha i krpelja ispitano je i u laboratorijskim i u terenskim ispitivanjima.
The effectiveness of Broadline against feline lungworm was investigated in a field study in Italy.
Djelotvornost VMP-a Broadline protiv plućnog crva u mačaka istražena je u terenskom ispitivanju u Italiji.
The effectiveness of Broadline against fleas and ticks was investigated in three field studies.
Djelotvornost VMP-a Broadline protiv buha i krpelja istražena je u tri terenska ispitivanja.
The effectiveness of Broadline against Notoedres cati was examined in a laboratory study with 18 naturally infested cats.
Djelotvornost VMP-a Broadline protiv šugarca Notoedres cati ispitana je u laboratorijskom ispitivanju koje je uključivalo 18 prirodno infestiranih mačaka.
The effectiveness of Broadline against worms was investigated in one EU field study involving cats of various ages and both genders with tapeworm or roundworm infections or both.
Djelotvornost VMP-a Broadline protiv crva ispitana je u jednom terenskom ispitivanju na području EU-a koje je uključivalo mačke različitih dobi i oba spola s infestacijama trakavicama ili oblićima ili oboje.
The effectiveness of Ceplene has been studied in one main study involving 320 adults with AML who were in remission following leukaemia treatment.
Djelotvornost lijeka Ceplene ispitana je u jednom glavnom ispitivanju koje je obuhvatilo 320 odraslih osoba oboljelih od AML-a koji su bili u remisiji nakon liječenja leukemije.
The effectiveness of Ceplene has not been fully demonstrated in patients older than 60 years of age.
Djelotvornost lijeka Ceplene nije u potpunosti dokazana u bolesnika starijih od 60 godina.
The effectiveness of Eliquis in preventing blood clots in veins following a hip or knee replacement has been investigated in two main studies involving a total of 8,464 patients.
Djelotvornost lijeka Eliquis u sprječavanju krvnih ugrušaka u venama nakon kirurške zamjene kuka ili koljena ispitana je u dva glavna ispitivanja koja su obuhvatila ukupno 8.464 bolesnika.